



Date: 27 December 2017

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office

and

Operational Office:

Suite 3, Level 4

828 Pacific Highway

Gordon NSW 2072

Australia

Board of Directors

Mr Peter Marks

Chairman

Non-Executive

Director

Dr Graham Kelly

Chief Executive Officer

Managing Director

Dr Ian Dixon

Non-Executive

Director

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

KAZIA THERAPEUTICS LTD AND NOXOPHARM LTD

Sydney, 27 December 2017: Noxopharm Limited (NOX:ASX) and Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) are pleased to announce the creation of a collaboration to support the future development of the Noxopharm lead program, NOX66.

Under the terms of the collaboration, Kazia will provide certain technical information and proprietary information that is expected to assist and expedite the successful development of NOX66. In return, Kazia has agreed to take a small equity interest in Noxopharm, which will help to align the future interests of both companies.

Kazia CEO, Dr James Garner, commented, "we are delighted to facilitate the future success of NOX66, and we look forward to assisting and following the progress of the program with keen interest."

Noxopharm CEO, Dr Graham Kelly, commented, "the collaboration with Kazia helps to ensure that the major clinical program planned in 2018 for NOX66 will proceed smoothly and with certainty. We look forward to providing our shareholders with data as the various clinical studies progress."

.....

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour. Idronoxil is a kinase inhibitor that works by inhibiting a range of enzymes including sphingosine kinase and PI3 kinase that regulate cell pro-survival mechanisms and which are over-expressed in cancer cells, as well as inhibiting external NADH oxidase Type 2 (ENOX 2) which is responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane of cancer cells and whose expression is limited to cancer cells. Inhibition of these enzymes results in disruption of key downstream pro-survival mechanisms including resistance mechanisms, sensitizing the cancer cell to the cytotoxic effects of chemotherapy drugs and radiotherapies.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

Investor & Corporate Enquiries:

Company Secretary:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

David Franks
T: +61 2 9299 9690
E: dfranks@fa.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.